Thymosin alpha 1 in combination with interferon alpha and ribavirin in chronic hepatitis C patients who are non-responders or relapsers to interferon alpha plus ribavirin.

Abbas Z, Hamid SS, Tabassum S, Jafri W

JPMA. The Journal of the Pakistan Medical Association1 Nov 2004Cited by 5 (Europe PMC)

PMID15623184PepBankPUB-15623184

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

01HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialSafety outcome
Minor adverse effects were observed during treatment with thymosin alpha‑1, interferon alpha and ribavirin in patients with chronic hepatitis C.
In plain wordsPatients with hepatitis C had only minor side effects on a regimen of three drugs including thymosin alpha‑1.
Peptide
Thymosin alpha-1
Outcome
Not applicableAdverse effects during treatment
Study
n = 11
Outcome group
Adverse events · Whole body
Source sentences
Summary
Minor adverse effects were observed during treatment with this combination therapy and no dose reduction or discontinuations were needed.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, 11 patients who relapsed (n=5) or did not respond (n=6) to previous INF-alpha-based therapy were retreated with combination Ta-1, INF-alpha and ribavirin for 12 months, and followed up for a further six months.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1562318403
02HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialSafety outcome
No dose reduction or discontinuation was needed in patients with chronic hepatitis C treated with thymosin alpha‑1, interferon alpha and ribavirin.
In plain wordsNo patient on a regimen of three drugs including thymosin alpha‑1 needed a lower dose or had to stop.
Peptide
Thymosin alpha-1
Outcome
No significant changeDose reductions or discontinuations
Study
n = 11
Outcome group
Adverse events · Whole body
Source sentences
Summary
no dose reduction or discontinuations were needed.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, 11 patients who relapsed (n=5) or did not respond (n=6) to previous INF-alpha-based therapy were retreated with combination Ta-1, INF-alpha and ribavirin for 12 months, and followed up for a further six months.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1562318404
03HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
In patients with chronic hepatitis C who had not responded before, one of the non-responders cleared HCV RNA during post-treatment follow-up on a regimen of thymosin alpha‑1, interferon alpha and ribavirin.
In plain wordsIn six hepatitis C patients who had not responded before, one cleared the virus after a regimen of three drugs including thymosin alpha‑1.
Peptide
Thymosin alpha-1
Outcome
Not applicableHCV RNA clearance in non-responders
Study
n = 6
Outcome group
Antiviral activity · Infection
Source sentences
Summary
One of the non-responders cleared the HCV RNA during the post-treatment follow-up.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, 11 patients who relapsed (n=5) or did not respond (n=6) to previous INF-alpha-based therapy were retreated with combination Ta-1, INF-alpha and ribavirin for 12 months, and followed up for a further six months.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1562318402
04HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
In patients with chronic hepatitis C who had relapsed, four of five had a sustained response to thymosin alpha‑1 with interferon alpha and ribavirin.
In plain wordsIn five hepatitis C patients who had relapsed, four had a lasting response to a regimen of three drugs including thymosin alpha‑1.
Peptide
Thymosin alpha-1
Outcome
Not applicableSustained response in relapsers
Study
n = 5
Outcome group
Antiviral activity · Infection
Source sentences
Summary
Four out of five relapsers had a sustained response.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, 11 patients who relapsed (n=5) or did not respond (n=6) to previous INF-alpha-based therapy were retreated with combination Ta-1, INF-alpha and ribavirin for 12 months, and followed up for a further six months.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1562318401

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
10 Oct 2026, 08:55 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.